Amarin Corporation plc $(AMRN)$ has announced new findings from in vitro studies presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The data provides insights into the potential mechanisms of action for the company's drug, VASCEPA®/VAZKEPA®, specifically involving eicosapentaenoic acid (EPA). The studies focused on the effects of EPA on lipoprotein(a) [Lp(a)] oxidation and its role in reducing cellular stress and inflammatory protein expression in endothelial cells. Preliminary results suggest that EPA may exert anti-inflammatory effects by modulating the nod-like receptor protein-3 (NLRP3) inflammasome in monocyte-derived macrophages. These findings indicate that EPA's benefits may extend beyond triglyceride lowering, potentially influencing cardiovascular risk factors through mechanisms such as autophagy and inflammasome activity.